Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSAgE study in older patients with metastatic colorectal cancer
NL-OMON58641Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Progression-free survival. Started Oct 2024; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON58641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58641.